Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer.

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer.

CTCA Clinical Research, LLC

Goodyear, Arizona, United States, 85338

California Cancer Care Associates

Encinitas, California, United States, 92024

University of California, San Diego

La Jolla, California, United States, 92037

CTCA Clinical Research, LLC

Zion, Illinois, United States, 60099

Washington University School of Medicine in St. Louis

Saint Louis, Missouri, United States, 63110

Roswell Park Cancer Institute

Buffalo, New York, United States, 14203

Ohio State Univeristy

Columbus, Ohio, United States, 43210

MD Anderson

Houston, Texas, United States, 77030

NEXT Oncology

San Antonio, Texas, United States, 78229

NEXT Virginia

Fairfax, Virginia, United States, 22031

Fred Hutch, University of Washington

Seattle, Washington, United States, 98109

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 28, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments